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Over half of regular consumers of tobacco, including
many young people state a desire to break from tobacco
dependence, but very few succeed in the long term.
OBJECTIVES: The objectives of the program can be
summed up as follows: to contribute to improving public
health knowledge; to understand the progress made by
smokers and ex-smokers; to anticipate success factors in
smoking cessation.
METHODS: In May 2001, 5000 user questionnaires
were distributed by GPs and pharmacists to smokers (S)
or ex-smokers (ES). The questionnaire included the most
frequently used tests, a socio-demographic profile, the in-
dividual’s smoking experience and a questionnaire of
knowledge of the smoking environment.
RESULTS: Presented here is the outcome of the analysis of
the first 700 responses, permitting a better understanding
of how smokers progress when they break from tobacco
dependence. The male/female ratio between smokers
(42%/58%) and ex-smokers (57%/43%) is statistically
significant (p  0.01), both for age (S/ES  39/46yrs) and
weight (S/ES  66/71kg). Forty three percent of ES said
they had a regular sporting activity as opposed to 26% of
S (p  0.001). The daily consumption of a cup of coffee
was different (S/ES  4.1/2.7) (p0.0001). There was no
difference with respect to alcohol consumption. Both
groups complained of being exposed to passive smoke:
S/ES  44%/41%. Forty-seven percent of the smokers
said they had a history of depressive problems, as opposed
to 36% of the former smokers p  0.02.
CONCLUSION: These first results confirm the growing
proportion of women who are tobacco dependent, the in-
fluence of passive smoking and the progress of the
smoker when he or she becomes an ex-smoker.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (Actos *NF) in combination therapy for patients
with type 2 diabetes in Finland.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics (Palmer et al., 2000) was
adapted to simulate long-term (80 years or until death)
management, health outcomes, resource utilisation and
treatment costs of patients with type2 diabetes. The
model accounts for most complications occurring in dia-
betes patients: nephropathy; retinopathy; acute myocar-
dial infarction; angina pectoris; stroke, and amputation.
The analysis was done from third-party-payer perspective
and costs figured relative to the year 2000. A 5% dis-
count rate was applied to costs and outcomes and sensi-
tivity analysis was performed to test the results.
RESULTS: Pioglitazone (PIO) 30 mg and metformin
(MF) were associated with longer life expectancy (15.16
years) than sulphonylureas (SU)/MF (14.47) or rosiglita-
zone (RSG) 8 mg/MF (15.06). PIO 30 mg/SU and PIO15
mg/SU are associated with the lowest number of serious
complications per 100 patients treated. For every 21 pa-
tients treated with PIO 30 mg/MF rather than SU/MF or
every 41 patients, respectively, for PIO15 mg/SU rather
MF/SU one complication is avoided. Combinations of
PIO 30 mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are as-
sociated with lower mortality than the other treatment
combinations available. Thus, for every 35 patients
treated with PIO 30 mg/MF rather than SU/MF one
death will be avoided after 15 years of treatment.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and may
represent a cost-effective use of scarce resources. It is nec-
essary to confirm the results of this theoretical model
once long-term effectiveness data with the compared al-
ternatives are available.
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OBJECTIVE: We assessed the incidence of diabetes in an
ambulatory population treated for the first time with ei-
ther olanzapine or risperidone.
METHODS: We conducted a population-based cohort
study using data from the Quebec drug benefit plan. In-
cluded in the cohort, all people who received a first pre-
scription of olanzapine or risperidone between 1/1/1997
and 8/31/1999, who were eligible for the drug plan, had
not been prescribed an antidiabetic drug or any atypical
antipsychotic for the six-month period preceding the first
olanzapine or risperidone prescription. Person-months of
follow-up were calculated as the amount of time from the
date of the first olanzapine or risperidone prescription to
the date of the first antidiabetic drug prescription. Those
who had a prescription for an antidiabetic drug were
considered as having diabetes. Subjects who discontinued
olanzapine or risperidone, who became non-eligible for
the drug plan and those who reached the end of the fol-
low-up period (8/31/2000) were censored at the event
date. We used a proportional hazard model to compute
the age- and sex-adjusted incidence-rate ratio (IRR) of
having diabetes among olanzapine users compared to ris-
peridone users.
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RESULTS: In all, 28,142 people were included in the co-
hort (12,945 olanzapine users and 15,197 risperidone us-
ers). The risk of developing diabetes was higher for those
exposed to olanzapine than for those exposed to risperi-
done, but this increase in risk was marginally statistically
significant (IRR: 1.209, 95 % CI: 1.001–1.460).
CONCLUSION: Compared to risperidone users, olanza-
pine users have a slightly higher risk of developing diabe-
tes. There is a need to extend this study over a longer ob-
servation period, as the risk of developing diabetes after
exposure to antipsychotic drugs is likely to increase with
time.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type2 diabetes.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by IMIB was adapted to simu-
late long-term management, health outcomes, resource
utilisation and treatment costs of patients with type2 dia-
betes. The model accounts for most complications in dia-
betes patients: nephropathy, retinopathy, acute myocar-
dial infarction, angina pectoris, stroke and amputation.
The analysis was done from a third-party-payer perspec-
tive and costs figured relative to the year 2000. A 6% dis-
count rate was applied and sensitivity analysis was per-
formed to test the results.
RESULTS: PIO 30 mg in combination with metformin
(MF) was associated with a higher life expectancy (14.82
years) than sulphonylureas (SU)/MF (14.03 years) or
rosiglitazone (RSG 8 mg/MF (14.67 years). Also, PIO-
based combinations were associated with the lowest
number of complications and deaths. For every 31 pa-
tients treated with PIO 30 mg /MF rather than SU/MF or
17 patients, respectively, for PIO 30 mg/SU rather than
MF/SU one complication was avoided. For every 27 pa-
tients treated with PIO 30 mg/SU instead of MF/SU, one
death was avoided. PIO was more expensive, but this was
offset by reductions in complications. The average pa-
tient-lifetime incremental total treatment cost with PIO
over alternatives ranged from 220,983 Spain Pesetas
(ESP) to 2,952,973 ESP. The undiscounted incremental
cost per life year gained (ICPLYG) of PIO 30 mg/MF rel-
ative to SU/MF was 3,660,692 ESP and relative to RSG
8 mg/MF 1,494,369 ESP. The discounted figures were
6,578,162 ESP and 1,913,919 ESP, respectively. The
ICPLYG of PIO 30 mg/SU relative to MF/SU was 3,344,145
ESP and 6,013,419 ESP after discounting. Finally, after
discounting, PIO 15mg/SU versus MF/SU and RSG 4 mg/SU
was associated with an ICPLYG of 7,556,100 ESP and
578,172 ESP, respectively.
CONCLUSION: Combined treatments with pioglitazone
improve survival and reduce complications in patients
with type 2 diabetes and represent cost-effective use of
scarce resources when judged against other therapeutic
interventions. It is necessary to confirm the results of this
model once long-term effectiveness data with the com-
pared alternatives are available.
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OBJECTIVE: Ischemic heart disease is the commonest
cause for morbidity and mortality in patients with diabe-
tes mellitus Type II (DMII). Treatment with biguanide
drugs has a beneficial effect on lipid profile, decreases in-
sulin resistance, procoagulant activity and body weight.
Drugs from the sulphonylurea group cause an increase in
insulin secretion, insulin resistance and weight gain. The-
oretically, lower rates of cardiovascular events would be
expected in patients treated with biguanides. The UKPDS
study showed decreased cardiovascular mortality in
obese diabetics, but several recent studies reported in-
creased mortality with metformin use. The objective of
our study was to compare cardiovascular disease in pa-
tients receiving either metformin or sulphonylurea.
METHODS: We compared the rates of revascularization
procedure in the year 2000 between patients with DMII
that were treated either with metformin or glibenclamide.
All received the drugs for at least five years. Demographic
parameters were similar between the groups. Data were
obtained from the computerized database of the largest
HMO in the country.
RESULTS: 140,757 patients were included in the study.
50.3% were on metformin and 49.7% on glibenclamide.
7601 underwent cardiac revascularization procedures. Of
these, 53 % were on glibenclamide and 47% on met-
formin. The risk of undergoing a revascularization proce-
dure was 1.13 times higher in patients treated with glib-
enclamide (P  .01).
CONCLUSION: The results of our study indicate that
patients with DMII treated with metformin have a lower
rate of cardiovascular procedures than patients treated
with glibenclamide. The use of this group of drugs may
decrease the morbidity, mortality and costs in diabetic
patients. More studies that include additional end points
are needed.
